title: [Clinical experience of application mildronate at recovery treatment of patients with displazia connecting fabric].
abstract: In order to evaluate the effectiveness mildronate in rehabilitative treatment in connective tissue dysplasia examined 240 patients (24,41 ± 7,62 years, 130 men). All patients were treated with 5 ml of mildronate 10% intravenously for 10 days, then 1 capsule (250 mg), 2 times per day for 4 months. The therapy showed a significant decrease in asthenic complaints, reducing the incidence of violations repolarization I (p<0.05) and II infarction (p<0.05), a significant increase in end-diastolic volume (p<0.05), stroke volume (p<0.05), left ventricular ejection fraction (p<0.05) by echocardiography, increased exercise tolerance with the normalization of reaction to physical stress on a dystonic normotonichesky, improved quality of life. During the treatment was not recorded adverse events in patients receiving the drug. Portability mildronate majority of patients described as good to very good (average 8.67 points).
authors.forename: G I
authors.initials: GI
authors.lastname: Nechaeva
authors.forename: O V
authors.initials: OV
authors.lastname: Drokina
authors.forename: G S
authors.initials: GS
authors.lastname: Dubileĭ
authors.forename: I V
authors.initials: IV
authors.lastname: Druk
mesh_terms: D000328:Adult; D001247:Asthenia / Q000188:drug therapy / Q000209:etiology; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000009:adverse effects; D003240:Connective Tissue Diseases / Q000150:complications*; D004333:Drug Administration Routes; D016903:Drug Monitoring; D017079:Exercise Tolerance / Q000187:drug effects; D005260:Female; D006331:Heart Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D006334:Heart Function Tests / Q000187:drug effects / Q000379:methods; D006801:Humans; D008297:Male; D008763:Methylhydrazines / Q000008:administration & dosage / Q000009:adverse effects; D009200:Myocardial Contraction / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D008763:Methylhydrazines; C050147:3-(2,2,2-trimethylhydrazine)propionate